Our docking studies clearly show that withaferin A acts as a bona fide ligand for both LXR-α and FXR and may activate both LXR-α and FXR and induce the expression of their target genes in NAFLD as a dual LXR/FXR receptor activator. The gene discussed is NR1H3; the disease is metabolic dysfunction-associated steatotic liver disease.